Unique ID issued by UMIN | UMIN000011370 |
---|---|
Receipt number | R000013304 |
Scientific Title | Phase II study of alternate-day treatment with S-1 as adjuvant chemotherapy for patients with lung cancer. |
Date of disclosure of the study information | 2013/08/05 |
Last modified on | 2019/03/28 13:53:42 |
Phase II study of alternate-day treatment with S-1 as adjuvant chemotherapy for patients with lung cancer.
Phase II study of alternate-day treatment with S-1 as adjuvant chemotherapy for patients with lung cancer.
Phase II study of alternate-day treatment with S-1 as adjuvant chemotherapy for patients with lung cancer.
Phase II study of alternate-day treatment with S-1 as adjuvant chemotherapy for patients with lung cancer.
Japan |
lung cancer
Chest surgery |
Malignancy
NO
A phase II study, that alternate-day S-1 is administered to patients with lung cancer,postoperatively, is carried out to confirm the feasibility,effectiveness and safety of the treatment.
Safety,Efficacy
Confirmatory
Pragmatic
Phase II
The ratio of the patients who completed the course
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
Adjuvant treatment of S-1 is administered on alternate-day for 1 year after surgery.
20 | years-old | <= |
Not applicable |
Male and Female
1. histologically proven non-small cell lung cancer with stage IB to IIIA
2. curative resection (R0) at the prior surgery
3.without any prior radiation therapy, chemotherapy for primary lung cancer.
4. age: 20< years old
5. PS(ECOG): 0 or 1
6. without any other severe diseases
WBC 3,000<= and => 12,000/mm3
Platelet 100,000/mm3 <=
Hemoglobin 9.0 g.dl <=
Total bilirubin 1.5 mg/dl =>
AST, ALT 100 IU/L <=
SPO2 90% <= or PaO2 60mmHg <=
Creatinin clearance 40 ml/min/body <=
**Cockcroft-Gault method is available
7.patients who can start adjuvant treatment within 8 weeks postoperatively.
8. written informed consents
1) patients who cannot take S-1
1.with severe allergic history against the ingredients of S-1.
2. with sever bone marrow suppression, renal or liver dysfunction
3. patients who need other fluorouracil
4. patients who need flucitosine.
2) with severe allergic history against medicines
3) with history of myocardial infarction in 6 months.
4)with other severe diseases (cardiac failure,mental disorder, infection or other severe complications)
5) with uncontrolled DM
6) with watery diarrhea
7) with double cancer and or multiple cancer
8)doctors' stop not to register to the study
25
1st name | Ichiro |
Middle name | |
Last name | Yoshino |
Chiba University Graduate School of Medicine
Department of General Thoracic Surgery
260-8670
1-8-1, Inohana, Chiba, 260-8670, Japan
043-222-7171
iyoshino@faculty.chiba-u.jp
1st name | Hidemi |
Middle name | |
Last name | Suzuki |
Chiba University Graduate School of Medicine
Department of General Thoracic Surgery
260-8670
1-8-1, Inohana, Chiba, 260-8670, Japan
043-222-7171
hidemisuzukidesu@yahoo.co.jp
Chiba University Graduate School of Medicine
Chiba University Graduate School of Medicine
Self funding
Chiba University Hospital Clinical Research Center
1-8-1, Inohana, Chiba, 260-8670, Japan
043-226-2616
prc-jim@chiba-u.jp
NO
2013 | Year | 08 | Month | 05 | Day |
Unpublished
25
Completed
2013 | Year | 03 | Month | 25 | Day |
2013 | Year | 05 | Month | 01 | Day |
2013 | Year | 05 | Month | 01 | Day |
2018 | Year | 06 | Month | 30 | Day |
2013 | Year | 08 | Month | 04 | Day |
2019 | Year | 03 | Month | 28 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000013304
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |